16.53

0.36% -0.06

Novocure Ltd (NVCR)

Overview News Price History Option Chain Financials Why NVCR Down? Discussions Forecast

Novocure Ltd stock is traded at $16.53, with a volume of 319.86K. It is down -0.36% in the last 24 hours and up +12.30% over the past month. NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Previous Close:

$16.59

Open:

$16.19

24h Volume:

319.86K

Relative Volume:

0.31

Market Cap:

$1.81B

Revenue:

$525.66M

Net Income/Loss:

$-192.74M

P/E Ratio:

-8.8871

EPS:

-1.86

Net Cash Flow:

$-120.97M

1W Performance:

-2.13%

1M Performance:

+12.30%

6M Performance:

+11.84%

1Y Performance:

+19.96%

1-Day Range:

$15.89

$16.97

1-Week Range:

$15.10

$17.69

52-Week Range:

$10.87

$24.73

Novocure Ltd Stock (NVCR) Company Profile

Name

Novocure Ltd

Sector

Healthcare (1181)

Industry

Medical Devices (155)

Phone

44 (0)15 3475 6700

Address

NO. 4 THE FORUM, ST. HELIER

Employee

1,453

Twitter

@novocure

Next Earnings Date

2024-10-30

Latest SEC Filings

NVCR's Discussions on Twitter

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight
Aug-04-23	Initiated	SVB Securities	Outperform
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-05-23	Reiterated	H.C. Wainwright	Buy
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy
Feb-08-22	Initiated	Loop Capital	Buy
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-20-22	Upgrade	Truist	Hold → Buy
Jan-03-22	Upgrade	Evercore ISI	Underperform → In-line
Jul-01-21	Downgrade	Mizuho	Buy → Neutral
Apr-14-21	Downgrade	Wedbush	Neutral → Underperform
Jan-25-21	Reiterated	Piper Sandler	Overweight
Sep-23-20	Initiated	Northland Capital	Outperform
Sep-18-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-17-20	Downgrade	Truist	Buy → Hold
Jun-01-20	Resumed	Oppenheimer	Perform
May-01-20	Downgrade	Oppenheimer	Outperform → Perform
Apr-09-20	Downgrade	Evercore ISI	In-line → Underperform
Mar-05-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-02-20	Downgrade	Evercore ISI	Outperform → In-line
Jul-29-19	Upgrade	SunTrust	Hold → Buy
Jul-26-19	Downgrade	JP Morgan	Overweight → Neutral
Jul-26-19	Downgrade	Wedbush	Outperform → Neutral
Mar-20-19	Initiated	SunTrust	Hold
Nov-02-18	Downgrade	Wells Fargo	Outperform → Market Perform
Jul-16-18	Initiated	Evercore ISI	Outperform
Apr-18-18	Reiterated	Mizuho	Buy
Feb-23-18	Reiterated	Mizuho	Buy
May-24-17	Upgrade	Wells Fargo	Market Perform → Outperform
Jul-29-16	Reiterated	Wedbush	Outperform
Jan-19-16	Initiated	Barclays	Underweight
Dec-02-15	Initiated	Deutsche Bank	Hold

View All

Novocure Ltd Stock (NVCR) Latest News

Nov 04, 2024

Novocure's COO Mukund sells shares worth $2,540 - Investing.com

Nov 04, 2024

Novocure's oncology president sells $9,530 in shares - Investing.com

Nov 04, 2024

Michal Nath Puri Sells 810 Shares of NovoCure Limited (NASDAQ:NVCR) Stock - MarketBeat

Nov 04, 2024

Novocure's oncology president sells $9,530 in shares By Investing.com - Investing.com Australia

Nov 04, 2024